Margriet Kwint

Safety and efficacy of reduced dose and margins 43 2 15. Schaake EE, Rossi MM, Buikhuisen WA, Burgers JA, Smit AA, Belderbos JS, et al. Differential motion between mediastinal lymph nodes and primary tumor in radically irradiated lung cancer patients. Int J Radiat Oncol Biol Phys. 2014;90:959-66. 16. Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320-33. 17. Wolthaus JW, Schneider C, Sonke JJ, van Herk M, Belderbos JS, Rossi MM, et al. Mid- ventilation CT scan construction from four-dimensional respiration-correlated CT scans for radiotherapy planning of lung cancer patients. Int J Radiat Oncol Biol Phys. 2006;65:1560-71. 18. van Herk M, Remeijer P, Lebesque JV. Inclusion of geometric uncertainties in treatment plan evaluation. Int J Radiat Oncol Biol Phys. 2002;52:1407-22. 19. Kwint M, Conijn S, Schaake E, Knegjens J, Rossi M, Remeijer P, et al. Intra thoracic anatomical changes in lung cancer patients during the course of radiotherapy. Radiother Oncol. 2014;113:392-7. 20. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol. 1993;138:923-36. 21. O’Rourke N, Roque IFM, Farre Bernado N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010:CD002140. 22. Hallqvist A, Bergstrom S, Bjorkestrand H, Svard AM, Ekman S, Lundin E, et al. Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trial. Lung Cancer. 2018;122:180-6. 23. Agrawal V, Coroller TP, Hou Y, Lee SW, Romano JL, Baldini EH, et al. Lymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLC. PLoS One. 2017;12:e0174268. 24. Walraven I, van den Heuvel M, van Diessen J, Schaake E, Uyterlinde W, Aerts J, et al. Long- term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab. Radiother Oncol. 2016;118:442-6. 25. Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer. 2007;43:114- 21. 26. Uyterlinde W, Belderbos J, Baas C, van Werkhoven E, Knegjens J, Baas P, et al. Prediction of acute toxicity grade >/= 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin. Clin Lung Cancer. 2013;14:541-8. 27. Chen C, Uyterlinde W, Sonke JJ, de Bois J, van den Heuvel M, Belderbos J. Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy. Radiother Oncol. 2013;108:337-41. 28. Dieleman EMT, Uitterhoeve ALJ, van Hoek MW, van Os RM, Wiersma J, Koolen MGJ, et al. Concurrent Daily Cisplatin and High-Dose Radiation Therapy in Patients With Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018;102:543-51.